Phase II study of 3-weeks cycle of S-1 as first-line for advanced pancreatic cancer (PACS-3)
- Conditions
- advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000011179
- Lead Sponsor
- Gifu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 70
Not provided
1) Pulmonary fibrosis or interstitial pneumonia. 2) Watery diarrhoea. 3) Active infections, excluding viral hepatitis. 4) Serious complications (e.g. heart failure, renal failure, hepatic failure, haemorrhagic peptic ulcer, intestinal paralysis, intestinal obstruction or poorly controlled diabetes). 5) Moderate or severe ascites or pleural effusion requiring treatment. 6) Metastasis in the CNS. 7) Active double cancer. 8) Patients under treatment with flucytosine, phenytoin or warfarin potassium. 9) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy. 10) Severe mental disorder. 11) Judged ineligible by physicians for participation in the study from a safety viewpoint.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Progression free survival Response rate Safety